ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HRTX Heron Therapeautics Inc

3.27
0.00 (0.00%)
Pre Market
Last Updated: 12:00:20
Delayed by 15 minutes
Share Name Share Symbol Market Type
Heron Therapeautics Inc NASDAQ:HRTX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.27 3.25 3.32 5 12:00:20

Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024

24/04/2024 1:00pm

PR Newswire (US)


Heron Therapeautics (NASDAQ:HRTX)
Historical Stock Chart


From Mar 2024 to May 2024

Click Here for more Heron Therapeautics Charts.

SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.

The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally.  Please provide the operator with the passcode 1497932 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
iduarte@herontx.com
858-251-4400

(PRNewsfoto/Heron Therapeutics, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-to-report-first-quarter-2024-financial-results-on-tuesday-may-7-2024-302126066.html

SOURCE Heron Therapeutics, Inc.

Copyright 2024 PR Newswire

1 Year Heron Therapeautics Chart

1 Year Heron Therapeautics Chart

1 Month Heron Therapeautics Chart

1 Month Heron Therapeautics Chart